CASSAVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Cassava Sciences, Inc. on Behalf of Cassava Stockholders and Encourages Investors to Contact the Firm
News provided byBragar Eagel & Squire
Apr 22, 2022, 9:00 PM ET
NEW YORK, April 22, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) on behalf of Cassava stockholders. Our investigation concerns whether Cassava has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On April 18, 2022, The New York Times published an article entitled “Scientists Question Data Behind an Experimental Alzheimer’s Drug.” The article addressed Cassava’s experimental Alzheimer’s drug, simufilam, and reported that one of Cassava’s advisers, Dr. H.Y. Wang, had five papers he authored retracted from the scientific journal PLoS One after an in-depth investigation revealed “serious concerns about the integrity and the reliability of the results.”
On this news, Cassava’s stock price fell sharply during intraday trading on April 19, 2022.
If you purchased or otherwise acquired Cassava shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by email at email@example.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.